Pages

• Home
• About AMD
• About LumiThera
• About Photobiomodulation
• Careers
• Cart
• Checkout
• Clinical Research
• Contact Us
  • Valeda Locator
• EULA
• Events
• Help
• icon.svg
• My Account Dashboard
• News & Info
• Our Products
• Privacy Policy
• SiteMap
• Store
• Subscribe to our Mailing List
• Subscription Confirmed
• Terms and Conditions of Sale
• Terms of Use
• Thank you!
• Valeda

Posts by category

• Category: Articles
  • 13-Month Efficacy and Safety Evaluation of Multiwavelength Photobiomodulation in Nonexudative (Dry) Age-Related Macular Degeneration Using the Lumithera Valeda Light Delivery System
  • Non-Invasive Treatment of Early Diabetic Macular Edema by Multiwavelength Photobiomodulation with the Valeda Light Delivery System
  • Photobiomodulation use in ophthalmology – an overview of translational research from bench to bedside
  • A DOUBLE-MASKED, RANDOMIZED, SHAM-CONTROLLED, SINGLE-CENTER STUDY WITH PHOTOBIOMODULATION FOR THE TREATMENT OF DRY AGE-RELATED MACULAR DEGENERATION
  • Photobiomodulation as a Treatment in Dry AMD
  • The first clinical case of dry age-related macular degeneration treated with photobiomodulation and nutraceuticals: a protocol proposal
  • TORPA 1 and 2
  • Dry AMD Therapy Evolves with Photobiomodulation
  • Quantitative Analysis of Transcranial and Intraparenchymal Light Penetration in Human Cadaver Brain Tissue
  • Absorption of Monochromatic and Narrow Band Radiation in the Visible and Near IR by Both Mitochondrial and Non-Mitochondrial Photoacceptors Results in Photobiomodulation
  • Treatment with 670 nm Light Upregulates Cytochrome C Oxidase Expression and Reduces Inflammation in an Age-Related Macular Degeneration Model
  • Recharging Mitochondrial Batteries in Old Eyes. Near Infra-Red Increases ATP
  • Low-Level Laser Therapy Improves Vision in a Patient with Retinitis Pigmentosa
  • Photobiomodulation in the Treatment of Patients with Non-Center-Involving Diabetic Macular Oedema
  • 670nm Photobiomodulation as a Novel Protection Against Retinopathy of Prematurity: Evidence from Oxygen Induced Retinopathy Models
  • Increases in Central Retinal Artery Blood Flow in Humans Following Carotid Artery and Stellate Ganglion Irradiation with 0.6 to 1.6 mum Irradiation
  • Gene and Noncoding RNA Regulation Underlying Photoreceptor Protection: Microarray Study of Dietary Antioxidant Saffron and Photobiomodulation in Rat Retina
  • Photobiomodulation Protects the Retina from Light-Induced Photoreceptor Degeneration
  • Low-Level Light Therapy of the Eye and Brain
  • Mitochondrial Signal Transduction in Accelerated Wound and Retinal Healing by Near-Infrared Light Therapy
  • Therapeutic Photobiomodulation for Methanol-Induced Retinal Toxicity
  • Power Games
• Category: Press Releases
  • LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision
  • LumiThera Announces First CPT Code to Report Photobiomodulation Therapy in Retinal Disease – First Step Toward Reimbursement
  • LumiThera Announces Initiation of EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration (AMD)
  • LumiThera Provides Update on FDA Review of Valeda Treatment for Dry AMD Patients
  • LumiThera Receives Notice of Award for National Eye Institute Grant to Support a 3rd Year Extension to LIGHTSITE III, the U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration
  • LumiThera Announces Sustained Vision Improvement for 24 months in Dry Age-Related Macular Degeneration Subjects from US LIGHTSITE III Clinical Trial Data
  • LumiThera Announces Fast Company Honors AdaptDx Pro As An Innovation and Design Award Winner
  • LumiThera, Inc. Announces Purchase of MacuLogix Assets
  • LumiThera Presents US LIGHTSITE III Trial Data Showing Improvement in Vision in Intermediate Dry Age-Related Macular Degeneration
  • Diopsys, Inc. Announces Move to Expanded Headquarters in New Jersey
  • LumiThera Announces US LIGHTSITE III Clinical Trial Meets Primary Efficacy Endpoint in Improving Vision in Dry Age-Related Macular Degeneration Subjects
  • LumiThera Secures Financing to Support Commercial Activities
  • LumiThera, Inc. Announces Completion of Diopsys, Inc. Acquisition
  • LumiThera, Inc. Announces Creation of a Light-based Theranostic Approach to Treat Ocular Disease with Acquisition of Diopsys, Inc.
  • LumiThera Announces Valeda Treatments Improve Vision and Retinal Function in Top Line Data from the ELECTROLIGHT Pilot Study in Dry AMD patients
  • LumiThera Presents Valeda Treatment Benefits for Photobiomodulation in Early Patients with Diabetic Retinopathy and Macular Edema
  • LumiThera Announces Top Line Data in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
  • LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD patients
  • LumiThera listed as 1 of 10 Startups to Watch
  • LumiThera Completes Patient Enrollment in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration
  • LumiThera Announces Ryan Montecucco as General Counsel
  • LumiThera and Diopsys Announce Collaboration and Enrollment of First Subject in the ELECTROLIGHT Study in Dry AMD patients
  • LumiThera Receives Notice of Award for $1.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Diabetic Retinopathy and Macular Edema
  • LumiThera Closes Series C Round of Financing
  • LumiThera to Expand Research into Diabetic Retinopathy for Valeda® Light Delivery System
  • LumiThera Adds Daniel Bertholet to Board of Directors
  • LumiThera Closes 2nd Tranche of Series C Financing
  • LumiThera Enrolls First Patient in the U.S. Multi-Center, LIGHTSITE III Clinical Study to Treat Dry Age-Related Macular Degeneration
  • Valeda Light Delivery System Receives 2019 Medical Design Excellence Award
  • LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration
  • LumiThera Receives Seattle Business Magazine 2019 Leaders in Health Care Award for Achievement in Medical Technology
  • LumiThera Announces an Agreement with Andrec Corporation S.A. to Distribute the Valeda Light Delivery System in Colombia and Several Latin American Countries
  • LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration
  • LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy
  • Optos Announces Collaboration for Monitoring and Treating Dry Age-Related Macular Degeneration in Europe
  • LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe
  • LumiThera, Inc. Selected to Present at the Ophthalmology Innovation Summit 2018 at the American Academy of Ophthalmology, Chicago, IL
  • LumiThera, Inc. to Debut Valeda Light Delivery System at the 18th Congress of the European Society of Retina Specialists (EURETINA) in Vienna, Austria
  • LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark
  • LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data
  • LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)
  • LumiThera, Inc. to Participate in the 2018 Glaucoma 360 in San Francisco
  • LumiThera to Present at the Digital Medicine and MedTech ShowcaseTM Annual Conference on January 10, 2018
  • LumiThera Unveils LIGHTSITE I Dry AMD Clinical Interim Data
  • LumiThera Closes Series B Round of Financing
  • LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017
  • LumiThera Presents Results of TORPA II Clinical Study at the Association for Research in Vision and Ophthalmology (ARVO) Conference
  • LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016
  • LumiThera Obtains Approval by Health Canada to Start Age-related Macular Degeneration Clinical Study
  • LumiThera Receives Notice of Awards for two National Eye Institute Grants
  • LumiThera Receives LSDF Commercialization Grant Award
  • Retired Congressman Norman Dicks Joins LumiThera’s Advisory Team
  • Retired Major General Gale Pollock Joins LumiThera’s Scientific Advisory Board
  • Video Introduction
  • LumiThera Receives Notice of LSDF Grant Award